Objective: To study the epidemiological, diagnostic, therapeutic and progressive aspects of prostate cancer with PSA ≥ 100 ng/ml at Owendo University Hospital. Methodology: Prospective, descriptive study with progressive inclusion of cases, conducted from November 2021 to October 2024. It involved 40 patients admitted to the general surgery department of Owendo University Hospital. The variables studied were age, medical history, comorbidities, reason for consultation, duration of symptoms, PSA kinetics, nadir time, castration resistance time, Gleason score and duration of treatment. Results: The prevalence was 35.5% of CaP cases. The average age was 66.9 ± 6.1 years. All patients had lower urinary tract symptoms and 95% of cases had a pathological prostate on digital rectal examination. Stages T2 and T3 accounted for 32.5% and 55% of cases. Forty-seven per cent of cancers were low grade. CT-TAP revealed 47.5% of metastatic cancers with 45.0% of bone metastases. Treatment consisted of first-generation hormone therapy, chemotherapy, and radical prostatectomy in 95%, 20%, and 5% of cases, respectively. Symptoms regressed in 60% of cases, and the nadir time was 10.9 months. During the 24-month follow-up period, 11 patients achieved a PSA level below 4 ng/ml and 6 cases showed resistance to castration after an average of 15 months of treatment. The mortality rate was 20%. Conclusion: Prostate cancer with PSA levels above 100 ng/ml is common in our country. A PSA level ≥100 ng/ml does not necessarily indicate high-grade prostate cancer, let alone metastasis. Treatment with hormone therapy and even definitive local treatment allows for effective control of the disease.
Adrien et al. (Tue,) studied this question.